🔗 Share this article

As America continues making unprecedented adjustments to its immunization schedules, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by casting doubt on coronavirus vaccines during the global health crisis and has focused upon potential deaths following COVID-19 immunization in her short tenure at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Immunization Schedule

Agency leaders were set to announce radical revisions to the childhood vaccination calendar in December, synchronizing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would place the US out of step with many the global community with insufficient data for improved outcomes. This reveal has been pushed back until the next year.

In place of Vinay Prasad, Høeg is set to speak at the meeting. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the office this calendar year.

A New Direction at the FDA

The acting appointment might represent a tighter collaboration between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad solidify control at the regulatory agency – and it suggests a greater focus upon dismantling previously authorized vaccines at the FDA.

The new acting director has repeatedly called for discontinuing some pediatric shot schedules in the US in order to be more in line with the Danish model, a society with nationalized medicine and a number of inhabitants roughly the size of the state of Wisconsin.

To date public appearances, she has continued to focus on immunizations – traditionally the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Doubts Over Expertise

Høeg has no obvious track record in drug development, approval processes or leadership, which has been typical for former heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the FDA chief and CBER since March.

“It seems she lacks to have the necessary background” for overseeing the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a scientific study. She is not versed in running a sizeable institution. She lacks background in drug approvals.”

Previous directors of CBER would “understand laws and regulations and the research of drug development”, said Janet Woodcock. “Objectively, she has not acquired the sort of resume that prior appointees who headed the center have had.”

The drug center has an vast range of responsibilities at the FDA, the former commissioner pointed out.

“The public just focuses on the new drug program, but the off-patent medication office approves a multitude of generic drugs. There’s a biosimilars program, non-prescription drug unit and so forth, and every single one have to be looked after,” Dr. Woodcock explained. “The responsibility you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a major administrative component to the role, which manages more than 5,000 personnel. “It’s a massive administrative position, if you do it right,” the former official added.

Response and Disputed Initiatives

Regarding concerns about Høeg’s qualifications and whether this appointment signifies greater collaboration among regulatory chiefs on vaccines, a representative responded that the “concerns are based on inaccurate premises”.

“Her experience is consistent with the functions of her job,” the representative explained, noting the time Dr. Høeg spent advising the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg takes over the agency head's controversial expedited review system, a disputed rapid drug-approval program that reportedly concerned her former heads. “By what process are these drugs being chosen for this expedited pathway? Who takes the choices?” Dr. Howard asked. “There is a lot of lack of transparency going on at the agency right now.”

Broadly speaking, he said, “the FDA looks to be trending towards more relaxed rules of pharmaceuticals, with the exception of immunizations.”

Documented History on Immunizations

Regarding vaccines, Høeg has a more documented, if troubling, past, critics said. She authored a study using unverified crowd-sourced reports to determine the incidence of heart inflammation following Covid vaccination. She consulted for the state of Florida top health official Joseph Ladapo, who was said to have changed statistics to indicate Covid vaccinations are more dangerous than they are.

Included in her “wish list” for the incoming administration featured altering regulations for recently developed shots and discontinuing “non-essential” vaccines, she said post-election on a online show. At the FDA, Høeg has according to sources proposed excluding adolescent males from obtaining Covid vaccines.

“She’s an complete true believer who begins with her preconceived notions and tailors the evidence to fit the evidence in a very disingenuous, untruthful fashion,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of fellow dissenters, {like|